:: Volume 12, Issue 5 (September-October 2018) ::
IJT 2018, 12(5): 4-1 Back to browse issues page
Antiproliferative Effect of Aspirin on Colorectal Cancer Cell Line
Malihe Bagheri , Amir Reza Hesari , Parisa Zia Sarabi , Hamid Reza Rahimi , Maryam Baazm , Faezeh Ghasemi
MSc of Medical Biotechnology, Student Research Committee, Faculty of Medicine, Arak University of Medical Sciences, Arak, Iran.
Abstract:   (153 Views)
Background: Nonsteroidal anti-inflammatory drugs (NSAIDs) such as Aspirin may have anticancer properties, and can be effective as a novel strategy for the treatment of colorectal cancer (CRC). The aim of this study was to assess the cytotoxic effects of Aspirin drug in CRC cell lines compared with Oxaliplatin drug in vitro.
Methods: Cell viability was assessed after treatment of SW742 and SW480 cells with Aspirin and Oxaliplatin by MTT assay, and the amount of IC50 was determined. Statistical analysis was performed through one-way ANOVA and Tukey multiple range analysis (SPSS 19.0 software (P <0.05).
Results: Aspirin and Oxaliplatin considerably inhibited the growth of SW742 and SW480 cell lines. SW742 cell line was more sensitive to Aspirin than SW480 cell line. The cytotoxic effect of Oxaliplatin was higher than Aspirin in both cell lines.
Conclusions: This study demonstrated that both Aspirin and Oxaliplatin have cytotoxic effects on SW742 and SW480 cell lines in vitro. Thus, Aspirin may be considered as a therapeutic agent in CRC, however, further in vivo investigations are required to fully establish this effect.
Keywords: Aspirin, Colorectal Cancer, MTT Assay, Oxaliplatin
Full-Text [PDF 1286 kb]   (104 Downloads)    
Type of Study: Research | Subject: General
References
1. 1. Torre LA, Bray F, Siegel RL, Ferlay J, Lortet‐Tieulent J, Jemal A. Global cancer statistics, 2012. CA: a cancer journal for clinicians. 2015;65(2):87-108. [DOI:10.3322/caac.21262]
2. Siegel R, Miller K, Jemal A. Cancer Statistics, 2017 CA Cancer J Clin 2017; 67: 7-30. External Resources Pubmed/Medline (NLM) Crossref (DOI). [DOI:10.3322/caac.21387]
3. Rezaianzadeh A, Safarpour AR, Marzban M, Mohaghegh A. A systematic review over the incidence of colorectal cancer in Iran. Annals of colorectal research. 2015;3(1).
4. Johnson CM, Wei C, Ensor JE, Smolenski DJ, Amos CI, Levin B, et al. Meta-analyses of colorectal cancer risk factors. Cancer causes & control. 2013;24(6):1207-22. [DOI:10.1007/s10552-013-0201-5]
5. Bloem LT, Lourenço RDA, Chin M, Ly B, Haas M. Factors impacting treatment choice in the first-line treatment of colorectal cancer. Oncology and therapy. 2016;4(1):103-16. [DOI:10.1007/s40487-016-0020-4]
6. Van Cutsem E, Cervantes A, Nordlinger B, Arnold D. Metastatic colorectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of oncology. 2014;25(suppl_3):iii1-iii9.
7. Ricchi P, Zarrilli R, Di Palma A, Acquaviva A. Nonsteroidal anti-inflammatory drugs in colorectal cancer: from prevention to therapy. British journal of cancer. 2003;88(6):803. [DOI:10.1038/sj.bjc.6600829]
8. Ghosh N, Chaki R, Mandal V, Mandal SC. COX-2 as a target for cancer chemotherapy. Pharmacological reports. 2010;62(2):233-44. [DOI:10.1016/S1734-1140(10)70262-0]
9. Jiang M-j, Dai J-j, Gu D-n, Huang Q, Tian L. Aspirin in pancreatic cancer: chemopreventive effects and therapeutic potentials. Biochimica et Biophysica Acta (BBA)-Reviews on Cancer. 2016;1866(2):163-76. [DOI:10.1016/j.bbcan.2016.08.002]
10. Awtry EH, Loscalzo J. Aspirin. Circulation. 2000;101(10):1206-18. [DOI:10.1161/01.CIR.101.10.1206]
11. Simmons DL, Botting RM, Hla T. Cyclooxygenase isozymes: the biology of prostaglandin synthesis and inhibition. Pharmacological reviews. 2004;56(3):387-437. [DOI:10.1124/pr.56.3.3]
12. Langley R, Burdett S, Tierney J, Cafferty F, Parmar M, Venning G. Aspirin and cancer: has aspirin been overlooked as an adjuvant therapy? British journal of cancer. 2011;105(8):1107. [DOI:10.1038/bjc.2011.289]
13. Wang D, DuBois RN. The role of COX-2 in intestinal inflammation and colorectal cancer. Oncogene. 2010;29(6):781. [DOI:10.1038/onc.2009.421]
14. Patrignani P, Patrono C. Aspirin and cancer. Journal of the American College of Cardiology. 2016;68(9):967-76. [DOI:10.1016/j.jacc.2016.05.083]
15. Chan AT, Ogino S, Fuchs CS. Aspirin use and survival after diagnosis of colorectal cancer. Jama. 2009;302(6):649-58. [DOI:10.1001/jama.2009.1112]
16. Sefidabi R, Mortazavi P, Hosseini S. Antiproliferative effect of berberine on canine mammary gland cancer cell culture. Biomedical reports. 2017;6(1):95-8. [DOI:10.3892/br.2016.809]
17. Goel A, Chang DK, Ricciardiello L, Gasche C, Boland CR. A novel mechanism for aspirin-mediated growth inhibition of human colon cancer cells. Clinical Cancer Research. 2003;9(1):383-90.
18. Kısmet K, Akay MT, Abbasoǧlu O, Ercan A. Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detection and Prevention. 2004;28(2):127-42. [DOI:10.1016/j.cdp.2003.12.005]
19. Voutsadakis IA, Patrikidou A, Tsapakidis K, Karagiannaki A, Hatzidaki E, Stathakis NE, et al. Additive inhibition of colorectal cancer cell lines by aspirin and bortezomib. International journal of colorectal disease. 2010;25(7):795-804. [DOI:10.1007/s00384-010-0939-0]
20. Subbegowda R, Frommel TO. Aspirin toxicity for human colonic tumor cells results from necrosis and is accompanied by cell cycle arrest. Cancer research. 1998;58(13):2772-6.


XML     Print



Volume 12, Issue 5 (September-October 2018) Back to browse issues page